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ABSTRACT
Objective: Assays based on interferon c (IFNc) are an
exciting new development for screening for latent
tuberculosis infection (LTBI) in adults, but there are limited
data on their effectiveness in children. Nevertheless new
National Institute for Health and Clinical Excellence (NICE)
guidelines recommend their use when screening paedia-
tric tuberculosis (TB) contacts. We evaluated the potential
effect of the new NICE guidelines on current paediatric
practice.
Design: Children screened for TB who had had an IFNc
assay performed (QuantiFERON-TB Gold (QFG)) were
included. Actual outcomes from existing guidelines were
compared with those that would have been obtained
using NICE guidelines.
Results: QFG assays were performed on 120 children,
103 as part of TB contact tracing. Six of the 120 (5%)
were QFG positive, and seven of the 120 (6%) were
indeterminate. Where both Mantoux and QFG results
were available, these agreed in 62/104 (60%) of cases.
QFG tests were more likely to correlate with a negative
Mantoux (98% agreement) than with a positive Mantoux
(11% agreement). Management outcomes differed for 23/
103 children seen as part of TB contact tracing. Only one
(1%) of these had an indeterminate QFG result. 17 (85%)
fewer children would have been given LTBI treatment
(chemoprophylaxis) and two (2%) children with possible
TB would not have been identified using NICE guidelines.
Conclusion: New NICE guidelines for the use of IFNc-
based tests for TB screening will reduce the number of
children treated for presumed LTBI. Long-term prospec-
tive studies are needed to determine the number of
children with positive Mantoux tests but negative IFNc
results who are not given LTBI treatment yet later
develop TB.
In March 2006 National Institute for Health and
Clinical Excellence (NICE) tuberculosis (TB) guide-
lines1 replaced the British Thoracic Society (BTS)
guidelines,2 introducing the first new diagnostic tests
for detecting infected TB contacts for 100 years.
Two new commercially available in vitro tests,
QuantiFERON-TB Gold (QFG), (Cellestis Ltd,
Victoria, Australia) and T Spot TB (Oxford
Immunotech, UK), use the fact that T cells
stimulated by antigens specific to Mycobacterium
tuberculosis (MTB) produce interferon c (INFc).3
Either IFNc (QFG) or IFNc-secreting cells (T Spot
TB) are measured. Compared with the tuberculin
skin test (TST) they are less subjective, and by
using MTB-specific antigens the risk of false
positive results owing to cross-reactivity with
BCG or non-tuberculous mycobacterium (NTBM)
is reduced.3 False positives may still occur with
other less common NTBM species.3
Data in adults suggest that IFNc tests are
sensitive to active TB and are as good or better
than the TST in detecting LTBI.3 4 There are little
data exploring their use in children5–7 14 or routine
clinical practice.8 9 The actual effect of introducing
these tests on screening procedure and outcomes is
unknown.
Under NICE guidelines, patients with positive
Mantoux results (or for whom Mantoux testing
may be unreliable) undergo IFNc testing, if
available. The results determine further clinical
decision-making.
After using QFG as an additional test in our
children’s TB clinic for 18 months we compared
practice and outcomes under current local TB
guidelines against those that would have occurred
if NICE guidelines had been followed.
METHODS
Children on whom QFG tests were performed in
Newcastle General Hospital between March 2004
and November 2005 were identified from Health
Protection Agency (HPA) laboratory records. Age
and BCG status, reason for testing, Mantoux
result, CXR result and clinical details were
obtained from hospital records and our children’s
TB database.
QFG was performed according to the manufac-
turer’s instructions. Whole blood was incubated
with both a negative (nil) and positive (mitogen)
control as well as with MTB antigens. IFNc was
detected using an enzyme-linked immunosorbent
assay. Results were recorded as positive, negative
or indeterminate. A large response to the negative
control (.8.0 IU/ml) or failure to respond to the
positive control (,0.5 IU/ml) in the face of a
negative TB antigen result (,0.35 IU/ml above nil
control or >0.35 and ,25% of nil value) was
designated indeterminate.
Expected treatment outcomes for each child
were defined using NICE TB guidelines and
Newcastle’s Paediatric TB guidelines (table 1).
Newcastle TB guidelines are adapted from the
BTS 2000 guidelines;2 the assessment process
differs but outcome and management points are
the same. Although all children underwent a QFG
test, in the analysis of comparative management
outcomes, those who would not be offered an IFGc
test following the NICE algorithm were assigned
to ‘‘no QFG test’’.
The audit was registered with The Newcastle
upon Tyne Hospitals NHS Trust.
RESULTS
The QFG test was performed on 120 children
(table 2), aged 4 months–16 years, mean 10 years;
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56/120 (47%) had previously received BCG. Of these 120, six
(5%) were QFG positive, and seven (6%) indeterminate (table 3).
All but one of those with non-tuberculosis mycobacterial
lymphadenitis (NTBML) were QFG negative, with one inde-
terminate, and two out of three with BCG lymphadenitis were
negative, and one indeterminate.
Complete clinical details including concurrent Mantoux
result were found for 108/120, 11 had no Mantoux result
available, and one had QFG performed a long time after
Mantoux and treatment for TB disease (fig 1). Of the 46
Mantoux-positive children, five (11%) were also QFG positive.
Of the 62 Mantoux negative, one (2%) was QFG positive.
QFG and Mantoux results were the same in 32/45 (71%)
cases with prior BCG, and 30/59 (51%) without BCG and in
60% overall. Discordant results included 41 (39%) Mantoux-
positive but QFG-negative children and one (1%) Mantoux-
negative, QFG-positive child.
Seven (6%) had indeterminate results, five of these seven
were under 5 years (table 3). Indeterminates were found in two
out of seven (29%) of under 2 years olds, three out of 10 (30%)
of under 3 year olds and five out of 18 (28%) under 5 year old.
However, only one, a 12-year-old child, was tested as part of
contact tracing. Four children were re-tested, two were QFG
negative, two remained indeterminate.
Audit of local current practice and NICE guidelines
Actual and expected outcomes for 103 children who were seen
as part of TB screening and for whom both QFG and Mantoux
results were available were compared (table 4). Local guidelines
were followed in 99/103 (96%) cases; two children were
discharged when guidelines suggested chemoprophylaxis, and
two who should have been given BCG were lost to follow up.
Had NICE guidelines been followed QFG tests would have
been offered to 51/103 (49%); five (10%) of whom were QFG
positive, one (1%) QFG indeterminate. There would have been
no difference compared to actual outcome in 80/103 (78%),
with three treated for TB, two receiving LTBI treatment, 22
offered BCG and 53 discharged with only information and
advice about their TB risk. However, in 23 (22%) outcomes the
treatment would have been different; treatment for LTBI was
given in 18 where NICE would have given advice and
information only, in one advice only was given where NICE
recommended LTBI treatment, and two were not given BCG as
they were lost to the follow up. Seventeen (85%) fewer LTBI
treatments would be given under NICE than actually given.
Lastly, we treated two children for TB where NICE would
have given advice only. Both children had prior BCG and were
close contacts of a smear-positive TB case. One had a negative
Mantoux, thus QFG would not have been offered (and was
negative). Hilar lymphadenopathy was noted on CXR, but
neither CXR nor a full examination was advised by NICE. The
other had a positive Mantoux (29 mm), but a negative QFG
hence CXR and again a full examination would not be advised
by NICE; CXR was abnormal with hilar lymphadenopathy and
consolidation.
DISCUSSION
This is the first study to evaluate the potential effect of the new
NICE diagnosis guidelines on current paediatric practice.
Applying algorithms retrospectively gives a realistic indica-
tion of expected outcomes; the specific guidelines used for
screening for TB in our clinic are extremely well adhered too,
and any new guidelines would be equally well followed.
Table 1 Comparison between Newcastle Paediatric TB treatment
guidelines and NICE guidelines
Newcastle guidelines NICE guidelines
Indications for
giving triple
therapy
+/2Mantoux positive ,2 years
+Abnormal CXR Mantoux positive, +abnormal CXR,
+ clinical evidence TB
+Clinical evidence TB .2 years
Mantoux positive, +IFNc positive,
+abnormal CXR, +clinical evidence
Mantoux negative (smear-positive
contact)
IFNc positive, +clinical evidence
Criteria for
diagnosing latent
tuberculosis
infection (LTBI)
Mantoux positive +no
clinical evidence TB
Mantoux positive, +IFNc positive,
+no clinical evidence TB (+no prior
BCG when identified through
opportunistic screening)
Evidence of TB scars on
CXR; no history of adequate
treatment
Mantoux negative (smear-positive
contact) +IFNc positive, + no
clinical evidence
Evidence of TB scars on CXR, no
history of adequate treatment
Criteria for giving
BCG
No prior BCG No prior BCG, Mantoux ,6 mm
+MTX,5 mm And also if ,2 years: No prior
BCG, MTX .= 6 mm +IFNc
negative
+no clinical evidence TB
Criteria for
‘‘Inform and
Advise’’
Prior BCG, Mantoux negative,
+no clinical evidence of TB
Prior BCG, Mantoux negative
Opportunistic screening:
Mantoux 5–15 mm
Mantoux positive +IFNc negative
Criteria for positive Mantoux results in screening:
Contacts Newcastle: >5 mm no BCG; >15 mm prior BCG, NICE: >6 mm no BCG,
>15 mm prior BCG.
Opportunistic (eg, school referral) Newcastle and NICE:>15 mm with or without prior
BCG.
Table 2 Reason for referral to clinic
Contact of TB 41 (34.45%)
Positive tuberculin test (HEAF) at school pre-BCG screening 55 (46.22%)
Clinical suspicion of TB disease 14 (10.92%)
Non-tuberculosis mycobacterial lymphadenitis (NTBML) 5 (4.20%)
Post-BCG granulomatous lymphadenitis 3 (2.52%
New immigrant 2 (1.68%)
Table 3 Details of children testing QFG positive or indeterminate
QuantiFERON positive n = 6 (5%) QuantiFERON indeterminate n = 7 (6%)
5 Mantoux
positive
2 culture-confirmed TB
disease (lung and CNS)
1 Mantoux
positive
1.5 years; post-BCG
granulomatous lymphadenitis
1 TB contact with prior
history of TB
1 contact of Mantoux
+positive child
1 school referral
1 Mantoux
negative
1 contact of smear-
positive TB, prior BCG
and Mantoux 9 mm
3 Mantoux
negative
1.75 years; haematological
malignancy
3 years; recurrent infections
12 years; smear negative
contact with abdominal pain
3 Mantoux
not done
2.5 years; autoimmune
lymphoproliferative syndrome
(ALPS)
4 years; nontuberculous
mycobacteria lymphadenitis
3 years; Psoas abscess +
caseating granulomatous renal
infection
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Had NICE guidelines have been followed, 85% fewer children
would have been given chemoprophylaxis for LTBI after contact
with TB. This would make a significant reduction in prescribing
costs and unnecessary treatment for children. Nevertheless two
children treated for TB would have been ‘‘missed’’. However
neither was unwell despite significant CXR changes, and it is
not certain that they had TB. This reflects the difficulties in
diagnosing primary TB in children, and a trial of treatment is
often part of the diagnostic process.
Indeterminate results were less frequent than recently
reported8–10, and at 1% of those seen in the context of
community TB screening, they make the QFG test a feasible
routine test. Indeterminates were more common in the younger
child, although this may also be because of confounding factors
such as immunosuppression.8
The Mantoux test is well recognised as having good
sensitivity and specificity for TB disease, but in a low prevalence
population it has a positive predictive value as low as 0.27.11
IFNc tests are at least as sensitive and specific as Mantoux
tests in adults.4 There is far fewer data on their use in children,
although an ELISPOT IFNc test has shown 83% sensitivity for
children from South Africa, with 73% in HIV-positive children.5
As recognised by NICE within their guidelines, prospective
studies have yet to be published to determine what proportion
of IFNc-test-negative children go on to develop clinical disease.
However IFNc results do correlate better with risk factors and
degree of exposure in contacts of MTB than the TST does.6 7 12
This suggests a better positive predictive value for IFNc tests than
TSTs in low-prevalence populations. This explains the high false-
positive TST rate in these populations and a low positive
agreement between tests, as seen in our population. Conversely
a recent study in a high TB prevalence area suggested that the
TST correlated better than an IFNc test with recent exposure.13
The Mantoux test remains an effective screening tool with
proven benefits; treating LTBI on the basis of TST results
decreases the risk of active TB by 60%.14 The potential decrease
in false-positive Mantoux results with the introduction of IFNc
tests will significantly decrease the amount of LTBI treatment
given to children in contact with TB.
Within NICE guidelines there is a reliance on the superiority
of QFG over Mantoux; however, without a gold standard to
determine the absolute sensitivity and specificity of QFG in
Figure 1 Flow chart showing QFG
outcomes in relation to BCG and Mantoux
status.
Table 4 Actual and predicted outcomes after screening for TB when using Newcastle or NICE guidelines
Guideline outcomes under
Newcastle guidelines
(actual outcome)
Newcastle Predicted guideline outcomes under NICE
Mantoux
Total
Mantoux negative (77) Mantoux positive (26)
TotalNegative Positive QFG positive QFG negative
QFG not
suggested by
NICE QFG positive QFG negative
QFG not
suggested by
NICE
Number = 103 77 26 103 1 25 51** 4 21 1 103
Treatment for TB disease 1[1] 4[4] 5[5] 0 0 0 3 0 0 3
Treatment for LTBI 0[0] 22[20] 22[20] 1 0 0 1 0 1{{ 3
BCG 24[22*] 0 24[22] 0 7 17 0 0 0 24
Advice 52[52] 02 52[54] 0 18 34*** 0 21{ 0 73
*Lost to follow-up.
**Includes one child who tested QFG positive.
***Includes one child not tested in the algorithm (QFG normal), with abnormal CXR/pulmonary TB.
{Includes one child with abnormal CXR not given CXR/clinical exam under NICE as they were QFG negative, but actually treated for TB.
{{QFG not done as child ,2 years old with positive Mantoux.
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LTBI, it is difficult to tell with how much confidence we can
discharge children without treatment on the basis of QFG
results. Clinical judgement should be used in interpreting results
to ensure the best management outcome for the child.
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What this study adds
c Specific guidelines used for screening for TB are extremely
well adhered too, and any new guidelines would expect to be
equally well followed.
c Nearly half of children screened for tuberculosis would have an
IFNc test recommended when using NICE guidelines.
c Following NICE guidelines would result in 85% fewer children
being given treatment for LTBI after contact with TB.
What is already known on this topic
c UK guidelines for testing people in contact with infectious
tuberculosis are well established.
c NICE guidelines, introduced in 2006, recommend the inclusion
of an IFNc blood test in the assessment of contacts of
tuberculosis. Treatment is considered on the basis of a
positive IFNc test rather than a positive Mantoux test.
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